THE ALKALOID

Science, culture and capital — one dose at a time.

Issue #11 — May 19, 2026

THE DOSE

The First Real Crack in the Wall

On April 22, 2026, after fifty-six years, the federal government took its first concrete step away from treating cannabis as one of the most dangerous substances in American law. The Department of Justice issued a final order moving two narrow categories of cannabis from Schedule I to Schedule III of the Controlled Substances Act. FDA-approved drug products containing marijuana. State-licensed medical marijuana operations. Everything else remained Schedule I, alongside heroin.

The action was issued by Acting Attorney General Todd Blanche, executing the directive in President Trump's December 18, 2025 executive order. It used a relatively obscure legal mechanism, the treaty obligation exception under Section 811(d)(1) of the Controlled Substances Act, which allowed DOJ to bypass the standard notice-and-comment rulemaking process that had stalled rescheduling for years. Simultaneously, DOJ announced an expedited administrative hearing beginning June 29, 2026 and concluding July 15, 2026, to evaluate whether all cannabis, including adult-use recreational, should be moved to Schedule III through formal rulemaking.

It is the most consequential federal cannabis policy shift in over half a century. It is also far narrower than most public coverage suggests.

What the order actually changes is real but limited. State-licensed medical marijuana operators are no longer subject to Section 280E of the Internal Revenue Code, a provision that has effectively crushed cannabis businesses for decades by denying them ordinary business deductions. Effective federal tax rates for cannabis operators have run between 70 and 90 percent. Schedule III status removes that. Industry estimates suggest over $2 billion in industry-wide cash flow relief annually for medical operators. Treasury and the IRS have signaled that guidance will allow rescheduling to apply to the full 2026 tax year, and DOJ has encouraged Treasury to consider retroactive relief for prior years. Research access also expands significantly. Federally funded researchers, previously limited to using cannabis grown at the University of Mississippi, can now potentially work with high-quality licensed material.

What the order does not change is also significant. Adult-use recreational cannabis remains Schedule I. Hemp-derived cannabinoid products remain unaffected. Synthetic THC analogs like delta-10 are explicitly excluded. Bulk cannabis crops outside a medical licensing framework remain Schedule I. Banking restrictions remain in place pending separate legislative action like the SAFER Banking Act. The hundreds of thousands of Americans incarcerated or burdened with criminal records from cannabis convictions, disproportionately from Black and brown communities, receive no relief whatsoever. None of the equity provisions advocates have spent years building into reform proposals appear anywhere in the order.

The architecture of the partial rescheduling is itself worth understanding. By limiting Schedule III status to state-licensed medical operations, the federal government has effectively rewarded compliance with existing state regulatory frameworks while leaving the people and businesses outside those frameworks in the same legal position they occupied last year. The licensed industry, predominantly capitalized and largely white-owned, gets immediate tax relief and research access. Underground operators, legacy growers, and consumers in non-medical states get nothing. Equity is not absent from the order by oversight. It is absent by design.

Whether the June 29 hearing produces broader rescheduling, and whether litigation challenging the treaty obligation pathway succeeds or fails, will determine what this moment ultimately means. For now, the wall has cracked. It has not fallen.

QUICK HITS

• The expedited hearing matters more than the order. The June 29, 2026 administrative hearing, scheduled to conclude July 15, will compile the evidentiary record for full cannabis rescheduling. A final rule could be published as soon as late 2026, though litigation could delay that timeline significantly.
• Bill Barr is leading the opposition. Smart Approaches to Marijuana, the leading anti-rescheduling advocacy group, has reportedly retained former Attorney General Bill Barr to litigate against any final broader rescheduling action. Twenty-two Republican senators and twenty-six House Republicans formally urged the administration to abandon rescheduling before the December executive order was issued.
• DEA registration deadline approaching. Medical cannabis operators have a 60-day expedited application window for DEA Schedule III registration that closes June 22, 2026. Companies including Glass House Brands have already filed. Failure to register within the window may complicate ongoing operations.
• The 280E relief math is massive. For a medium-sized medical cannabis operator, the elimination of Section 280E can translate to millions of dollars in annual tax savings. The retroactive question, whether operators can amend returns going back to 2021 or 2022, is the largest single tax dollar question in the industry. Three years of retroactive relief could mean ten-figure refunds for the largest multi-state operators.
• Recreational operators face complex structuring decisions. Companies that operate both medical and recreational lines now need to segregate their books to claim 280E relief only on the qualifying medical portion. The structural complexity is creating significant work for cannabis-focused law firms and accounting firms.

That's the news. The analysis is below — Science Desk, Market Watch, and a closing thought.

SCIENCE DESK

What scheduling actually controls

The Controlled Substances Act was passed in 1970 as part of a broader federal reorganization of drug enforcement under the Nixon administration. The Act established five schedules based on three criteria: potential for abuse, accepted medical use, and likelihood of dependence. Schedule I, the most restrictive, was defined as substances with high abuse potential, no accepted medical use, and a lack of accepted safety for use under medical supervision. Cannabis was placed in Schedule I temporarily in 1970 pending the report of a commission. The commission, when it reported in 1972, recommended decriminalization. The recommendation was ignored. Cannabis has remained Schedule I for fifty-six years.

The medical determination has long been the most challenged element of the Schedule I classification. By 2026, thirty-nine states have legalized cannabis for medical use, with regulated programs, physician oversight, and licensed dispensaries. The contradiction between widespread state-level medical acceptance and federal denial of medical use has been the legal hinge on which rescheduling arguments have turned. In August 2023, the Department of Health and Human Services formally concluded that cannabis has accepted medical use and recommended Schedule III classification. That recommendation has now, after almost three years of bureaucratic process, been partially implemented.

What scheduling actually controls is regulatory infrastructure rather than legality. Schedule III substances are not legal. They are controlled, prescription-only, subject to DEA registration requirements, security standards, manufacturing quotas, and import-export restrictions. The relevant comparison for Schedule III is to drugs like ketamine, anabolic steroids, and certain barbiturates. These can be prescribed by doctors, dispensed by licensed pharmacies, and used by patients under medical supervision. They cannot be sold over the counter, possessed without prescription, or used recreationally without legal consequence.

This is why rescheduling, even broader rescheduling that emerges from the June 29 hearing, would not legalize cannabis. It would integrate cannabis into the existing medical pharmaceutical infrastructure. State-regulated recreational cannabis markets, which exist in 24 states, would remain in federal limbo regardless of scheduling outcome. The path to full federal legalization runs through Congress, not through scheduling adjustments.

MARKET WATCH

The market response to the April 22 rescheduling order has been substantial. Cannabis equities saw their largest single-day gains in years immediately following the announcement, with multi-state operators rising 30 to 50 percent on opening. The 280E relief alone justifies meaningful repricing of the entire sector. Companies that have paid effective federal tax rates above 70 percent for years suddenly have access to standard business deductions on the medical portion of their operations. For operators with significant medical exposure, the cash flow improvement is immediate and substantial.

The structural question for investors is the medical-versus-recreational split. Multi-state operators that have built their businesses primarily on adult-use sales in states like California, Michigan, and Massachusetts get less direct benefit than operators focused on medical-heavy markets like Florida, Pennsylvania, and New York. The companies positioned for the broadest benefit from the April order are those with substantial medical patient bases and existing state medical licensing infrastructure.

Watching the June 29 hearing remains the critical near-term catalyst for the sector. If the administrative process produces broader rescheduling covering adult-use markets, the 280E relief expands dramatically and the entire industry repricing thesis becomes much more aggressive. If the hearing stalls, faces litigation, or produces a narrower outcome, the current rally may prove premature. The Bill Barr litigation threat is real and could delay any final rule by months or longer.

Worth tracking separately is what happens to capital flows in psychedelic biotech as cannabis investment becomes more attractive on relative valuation. The two sectors have traded as somewhat substitutable speculative growth plays for years. Schedule III cannabis with 280E relief becomes a fundamentally different asset class than Schedule I cannabis was. The competitive landscape for capital allocation may shift meaningfully.

THE LAST WORD

There is a way to read the April 22 order that emphasizes what was achieved. Federal acknowledgment of cannabis medical use, the first since the Controlled Substances Act was passed. Tax relief for state-licensed medical operators worth billions in industry cash flow. Research access for federally funded scientists. An expedited path toward broader rescheduling through the June 29 hearing. After fifty-six years, the wall finally cracked. People who worked for decades to make this happen deserve to have that recognized.

There is also a way to read the same order that emphasizes what was avoided. No relief for the hundreds of thousands of people incarcerated under federal cannabis charges. No expungement of cannabis convictions. No equity provisions for communities devastated by enforcement. No protection for legacy operators who built underground cannabis culture through decades when the legal industry refused to acknowledge they existed. No benefit whatsoever to consumers in the 11 states without legal recreational cannabis. The rescheduling rewards the regulated industry while leaving everyone outside that industry exactly where they were.

Both readings are accurate. Both readings are incomplete without each other. What is true about this moment is that federal cannabis policy has finally moved in a direction that the medical evidence supported for decades. What is also true is that the form of the movement, the way it benefits some constituencies while ignoring others, reflects the political coalitions that built it more than the moral logic of who has been harmed by prohibition.

The most honest framing may be that this is the beginning of federal cannabis reform rather than its conclusion. The cracks in the wall are real. What gets built through those cracks, and who is included in the rebuilding, depends entirely on what advocates push for and what coalitions assemble around the June 29 hearing and the years of legislative work that will follow.

The plant has been waiting fifty-six years for the federal government to come to its senses. The people most harmed by prohibition have been waiting just as long for justice. The first has now partially arrived. The second still has not.

— The Alkaloid

Sources

1. U.S. Department of Justice — Final Order Placing FDA-Approved Marijuana Products and State Medical Marijuana in Schedule III: https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana
2. U.S. Department of the Treasury — Treasury, IRS Announce Process for Tax Guidance Following DOJ Final Order on Medical Marijuana Rescheduling: https://home.treasury.gov/news/press-releases/sb0471
3. Foley Hoag LLP — DOJ Immediately Reschedules State-Licensed Medical Cannabis to Schedule III: https://foleyhoag.com/news-and-insights/publications/alerts-and-updates/2026/april/doj-immediately-reschedules-state-licensed-medical-cannabis-to-schedule-iii-and-restarts-the-clock/
4. Gibson Dunn — DEA Downschedules State Medical Marijuana to Schedule III; Expedited Hearing Set: https://www.gibsondunn.com/dea-downschedules-state-medical-marijuana-to-schedule-iii-expedited-hearing-set-to-consider-broader-rescheduling/
5. Congress.gov — Legal Consequences of Rescheduling Marijuana (CRS Legal Sidebar LSB11105): https://www.congress.gov/crs-product/LSB11105
6. Foley & Lardner — Marijuana Some Products Reclassified to Schedule III: What It Means: https://www.foley.com/insights/publications/2026/04/dea-issues-long-awaited-final-order-rescheduling-certain-marijuana-products-to-schedule-iii-what-it-means-what-it-doesnt-and-what-comes-next/
7. Marijuana Policy Project — DOJ Reschedules State-Legal Medical Cannabis to Schedule III Questions and Answers: https://www.mpp.org/policy/federal/doj-reschedules-state-legal-medical-cannabis-to-schedule-iii-questions-and-answers/
8. The Marijuana Herald — CRS Says DOJ Order Could Ease 280E, Research Barriers: https://themarijuanaherald.com/2026/05/report-congressional-research-service-says-doj-medical-marijuana-order-could-ease-280e-research-barriers/

The Alkaloid publishes every Tuesday. Forward this to someone who needs the dose. Subscribe for full access: TheAlkaloid.com